Arca
Skip to content
Tools
Tools

FCGRT: IgG receptor FcRn large subunit p51

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Cell surface receptor that transfers passive humoral immunity from the mother to the newborn.

  • Drugs that act on it: 5
  • Approved: 2
  • In phases 1 to 3: 3
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on FCGRT, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Protein or peptide

Approved2

  • Efgartigimod alfa
  • Rozanolixizumab

Phase 32

  • Nipocalimab
  • Batoclimab

Phase 21

  • Orilanolimab

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Antibody480%
    • Protein or peptide120%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 5 act as: IgG receptor FcRn large subunit p51 antagonist; the rest name their own mechanism.
    Efgartigimod alfaApprovedargenx USProtein or peptideAntagonist—18—
    RozanolixizumabApprovedUCBAntibodyInhibitorIgG receptor FcRn large subunit p51 inhibitor6—
    NipocalimabPhase 3Johnson & JohnsonAntibodyAntagonist—12—
    BatoclimabPhase 3Immunovant Sciences GmbHAntibodyInhibitorIgG receptor FcRn large subunit p51 inhibitor0—
    OrilanolimabPhase 2AstraZeneca PharmaceuticalsAntibodyAntagonist—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov.
    A Study to Assess Pregnancy, Neonatal and Infant Outcomes in Participants Exposed to NipocalimabNipocalimab—Not yet recruitingJanssen Research & Development, LLC2026-11-04
    Efgartigimod in Anti-NMDA Receptor Encephalitis.Efgartigimod alfaPhase 2RecruitingBeijing Tongren Hospital2026-09-16
    Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)Efgartigimod alfaPhase 2Not yet recruitingBeijing Tiantan Hospital2026-09-08
    A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenNipocalimabPhase 1RecruitingJanssen Research & Development, LLC2026-06-25
    A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsEfgartigimod alfaPhase 2Not yet recruitingargenx2026-05-13
    Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)Rozanolixizumab—RecruitingCentre Hospitalier Universitaire de Nice2026-05-06
    A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRozanolixizumabPhase 3RecruitingUCB Biopharma SRL2026-03-11
    A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRozanolixizumabPhase 3RecruitingUCB Biopharma SRL2026-03-11
    A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusNipocalimabPhase 3RecruitingJanssen Research & Development, LLC2026-02-27
    Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisRozanolixizumabPhase 4Active, not recruitingUCB Biopharma SRL2025-11-24
    Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisEfgartigimod alfa, NipocalimabPhase 3RecruitingJanssen Research & Development, LLC2025-10-16
    Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC EfgartigimodEfgartigimod alfaPhase 4RecruitingCentre Hospitalier Universitaire de Nice2025-07-18
    A Study of Efgartigimod in Patients With IgG4-Related DiseaseEfgartigimod alfaPhase 2Active, not recruitingStanford University2025-06-17
    Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)Efgartigimod alfaPhase 1 / Phase 2Not yet recruitingM. Peter Marinkovich2025-06-09
    Efgartigimod for the Treatment of Guillain-Barré SyndromeEfgartigimod alfaPhase 2 / Phase 3Not yet recruitingZhongming Qiu2025-03-20
    Nipocalimab in Moderate to Severe Sjogren's DiseaseNipocalimabPhase 3Active, not recruitingJanssen Research & Development, LLC2024-12-19
    An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisRozanolixizumabPhase 3Active, not recruitingUCB Biopharma SRL2024-08-06
    A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)NipocalimabPhase 3RecruitingJanssen Research & Development, LLC2024-08-01
    A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)NipocalimabPhase 3RecruitingJanssen Research & Development, LLC2024-06-10
    A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)NipocalimabPhase 3RecruitingJanssen Research & Development, LLC2023-06-22
    A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)RozanolixizumabPhase 3Active, not recruitingUCB Biopharma SRL2021-09-30

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Autoimmune thrombocytopenic purpura
    0.41
    Immune system disorder
    0.37
    Neurodegenerative disease
    0.36
    Guillain-Barre syndrome, familial
    0.32
    Pemphigus vulgaris
    0.31

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5966, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P55899, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.